<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647294</url>
  </required_header>
  <id_info>
    <org_study_id>15-28745A</org_study_id>
    <nct_id>NCT02647294</nct_id>
  </id_info>
  <brief_title>Polyunsaturated Fatty Acids in Patients With NAFLD.</brief_title>
  <official_title>Nutrition-based Therapy of Liver Disease of Different Origin: Effect of n-3 Polyunsaturated Fatty Acid in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General University Hospital, Prague</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be
      randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months. At
      the beginning and at the end of the study basic clinical and anthropometric data, as well as
      parameters of liver steatosis and fibrosis will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be
      randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months. At
      the beginning and at the end of the study basic clinical and anthropometric data will be
      recorded and the following parameters will be tested:

      panel of biochemistry and liver function tests: triglycerides, cholesterol, HDLcholesterol,
      LDL-cholesterol, glucose, insulin, serum bilirubin, liver tests, thyroid hormones, bile
      acids and their metabolites, albumin, total protein.

      Bioactive metabolites, Inflammatory markers Non-invasive serum markers of liver fibrosis and
      steatohepatitis. Hyaluronic acid, NAFLD fibrosis score, cytokeratine-18 fragments.
      Ultrasonography with non-invasive measurement of fibrosis and steatosis, magnetic resonance
      spectroscopy for visceral and liver fat determination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with decreased liver fat content.</measure>
    <time_frame>12 months</time_frame>
    <description>Liver fat content in patients will be measured by magnetic resonance before and after the treatment. The number of patients with decreased liver fat content is expected to be higher in the treated group compare to placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with progression of liver fibrosis.</measure>
    <time_frame>12 months</time_frame>
    <description>Liver fibrosis will be measured by ultrasound (ARFI) before and after the treatment. The number of patients with no progression of fibrosis is expected to be higher in the treated group compare to placebo group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Polyunsaturated omega-3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo (soya oil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maxicor</intervention_name>
    <description>Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).</description>
    <arm_group_label>Polyunsaturated omega-3 fatty acids</arm_group_label>
    <other_name>n-3 polyunsaturated fatty acids</other_name>
    <other_name>n-3 PUFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metabolic syndrome and NAFLD

        Exclusion Criteria:

          -  Age below 18 years

          -  Gravidity

          -  Incompliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radan Bruha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General University Hospital in Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Radan Bruha, MD</last_name>
    <phone>0042022496</phone>
    <phone_ext>2506</phone_ext>
    <email>bruha@cesnet.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <state>Prague 2</state>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radan Bruha, MD</last_name>
      <phone>+420224962506</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 5, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General University Hospital, Prague</investigator_affiliation>
    <investigator_full_name>Radan Bruha</investigator_full_name>
    <investigator_title>Clinical associated professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
